The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 07, 2025
Filed:
Jul. 20, 2018
Universite DE Bordeaux, Bordeaux, FR;
Centre National DE LA Recherche Scientifique, Paris, FR;
Centre Hospitalier Universitaire DE Bordeaux, Talence, FR;
Inserm—institut National DE LA Sante ET DE LA Recherche Medicale, Paris, FR;
Universite D'angers, Angers, FR;
Centre Hospitalier Universitaire D'angers, Angers, FR;
Jean-Francois Augusto, Soucelles, FR;
Cecile Contin-Bordes, Merignac, FR;
Yahsou Delmas, Merignac, FR;
Patrick Blanco, Verdelais, FR;
Yves Delneste, Bouchemaine, FR;
Pascale Jeannin, Bouchemaine, FR;
Celine Beauvillain, Les Hauts D'Anjou, FR;
UNIVERSITE DE BORDEAUX, Bordeaux, FR;
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Paris, FR;
CENTRE HOSPITALIER UNIVERSITAIRE DE BORDEAUX, Talence, FR;
INSERM—INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, Paris, FR;
UNIVERSITE D'ANGERS, Angers, FR;
CENTRE HOSPITALIER UNIVERSITAIRE D'ANGERS, Angers, FR;
Abstract
The present invention concerns clusterin for use in the treatment of thrombotic microangiopathies, and a pharmaceutical composition comprising clusterin for use in the treatment of thrombotic microangiopathies, said composition not comprising von Willebrand factor protease. The present invention also concerns an ex vivo method for stratifying a patient suffering, or likely to be suffering, from TMA, comprising the following steps: 1) measuring, in a biological sample from said patient, the amount Lof clusterin, and 2) comparing the amount Lmeasured in step 1) with an amount Lof clusterin by calculating the score S1=L/L, in which: •If S1≤1, the patient is considered to be likely to benefit from a treatment of the TMA with clusterin, •If S1>1, the patient is not considered to be likely to benefit from treatment of TMA with clusterin.